Latest Tempus News & Updates

See the latest news and media coverage for Tempus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Tempus

AI-enabled precision medicine platform

tempus.com

Headquarters: Chicago, United States
Founded year: 2015
Company type: Public company
Number of employees: 3,100–5,000
Industry: Biotechnology & Medical Research

Last updated Today

Latest news about Tempus

In short: Tempus reported revenue growth, agreed to acquire Personalis, and expanded AI collaborations

Company announcements

October 26 Tempus

Tempus reports strong Q1 2026 revenue growth of 36%

Q1 revenue reached $348.1 million with 44% Insights growth and adjusted EBITDA near breakeven. The company reaffirms full-year guidance.

October 26 Tempus

Tempus reports strong Q2 2024 financial results with revenue growth

Q2 revenue rose 25.3% to $166 million. Non-GAAP gross profit increased 31.6%, and Adjusted EBITDA improved by $12.7 million quarter-over-quarter.

August 15 Tempus

Tempus reports Q2 revenue growth and announces Personalis acquisition

Revenue reached $382.5 million, up 22% year-over-year. The company also acquired Personalis for $16.25 per share to expand its oncology portfolio.

July 30 Tempus

Tempus reports Q2 revenue growth and profit

Revenue reached $382.5 million with a net income of $5.6 million. The company announced a $1.5 billion acquisition of Personalis.

Media coverage

Today AInvest

Tempus AI Posts Profit, But What’s Next?

Tempus AI reported $382.49M revenue and $5.64M net income in Q2 2026, showing strong growth and profitability.

October 22 MarketWatch

Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals

Tempus AI signed a multi-year deal with Bristol Myers Squibb to license oncological data and provide access to its artificial intelligence-powered platform. Under the terms...

September 21 The Globe and Mail

Recursion, Tempus Expand AI and RNA Collaboration Agreements

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

September 18 Stockstar

From Tempus AI to Desir: In the AI4S era, medical data is being re-priced

From September 14 to 17, Tempus AI rose for four consecutive trading days, with a cumulative increase of up to 36.18%. On the evening of September 17, the stock price surged by more than 16% intraday, reaching a high of $81.28, corresponding to a market capitalization of approximately $14.7 billion. This significant upward movement is primarily driven by the secondary market's re-pricing of high-quality, commercially reusable medical clinical data assets...

Never miss news about Tempus

Track Tempus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Tempus competitors & trending companies

Browse news for competitors to Tempus and other trending companies.